Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969742 | 1.00 | MEN1 (0.55) | MEN1KMT2APIK3CDMAPTATM | |
| SCHEMBL13635633 | 1.00 | MEN1 (0.55) | MEN1KMT2APIK3CDMAPTATM | |
| SCHEMBL425336 | 1.00 | MEN1 (0.55) | MEN1KMT2APIK3CDMAPTATM | |
| Water SCHEMBL28465237 | 0.97 | MEN1 (0.52) | MEN1KMT2APIK3CDMAPTATM | |
| Hydrochloric Acid SCHEMBL991507 | 0.97 | MEN1 (0.52) | MEN1KMT2APIK3CDMAPTATM | |
| SCHEMBL4924066 | 0.97 | — | — | |
| SCHEMBL101925 | 0.97 | — | — | |
| Iodide SCHEMBL31035714 | 0.94 | PIK3CD (0.48) | MEN1KMT2APIK3CDMAPTATM | |
| Ammonia Solution, Strong SCHEMBL18106936 | 0.94 | PIK3CD (0.48) | MEN1KMT2APIK3CDMAPTATM | |
| SCHEMBL426429 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947286-B1 | CONVERSION OF URANIUM HEXAFLUORIDE AND RECOVERY OF URANIUM FROM IONIC LIQUIDS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA LAS VE (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024150963-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 광주과학기술원 | 2024-07-18 | — | — | WO | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-11760654-B2 | Conversion of uranium hexafluoride and recovery of uranium from ionic liquids | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2023-09-19 | — | — | US | claimed |
| EP-3627608-B1 | POLYMER ELECTROLYTE FOR SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG ENERGY SOLUTION LTD (KR) | 2023-08-30 | — | — | EP | claimed |
| US-11699811-B2 | Bilayer component for a lithium battery | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-11 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-20220315443-A1 | CONVERSION OF URANIUM HEXAFLUORIDE AND RECOVERY OF URANIUM FROM IONIC LIQUIDS | The Board of Regents of the Nevada System of Higher Education on Behalf of the Univ of Nevada (US) | 2022-10-06 | — | — | US | claimed |
| US-20220278357-A1 | ANODELESS LITHIUM METAL BATTERY AND METHOD OF MANUFACTURING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-09-01 | — | — | US | claimed |
| US-11427480-B2 | Conversion of uranium hexafluoride and recovery of uranium from ionic liquids | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2022-08-30 | — | — | US | claimed |
| US-20220041464-A1 | CONVERSION OF URANIUM HEXAFLUORIDE AND RECOVERY OF URANIUM FROM IONIC LIQUIDS | The Board of Regents of the Nevada System of Higher Education on Behalf of the Univ of Nevada (US) | 2022-02-10 | — | — | US | claimed |
| EP-3947286-A1 | CONVERSION OF URANIUM HEXAFLUORIDE AND RECOVERY OF URANIUM FROM IONIC LIQUIDS | The Board of Regents of The Nevada System of Higher Education on behalf of the University of Nevada, Las Vegas (US) | 2022-02-09 | — | — | EP | claimed |
| US-20210305621-A1 | BILAYER COMPONENT FOR A LITHIUM BATTERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-09-30 | — | — | US | claimed |
| EP-3728252-A1 | 4-AZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3728264-A1 | DIAZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | claimed |
| CN-102199096-A | Method for synthesizing organic ionic compounds | JIANXING QIU | 2011-09-28 | — | — | CN | claimed |
| CN-100470920-C | Non-aqueous electrolyte battery | TOKYO SHIBAURA ELECTRIC CO (JP) | 2009-03-18 | — | — | CN | claimed |
| CN-1835272-A | Non-aqueous electrolyte battery | TOKYO SHIBAURA ELECTRIC CO (JP) | 2006-09-20 | — | — | CN | claimed |
| WO-1995020637-A2 | HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS | MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) | 1995-08-03 | — | — | WO | claimed |
| WO-1990010051-A1 | FUEL COMPOSITION FOR CONTROL OF INTAKE VALVE DEPOSITS | UNION OIL COMPANY OF CALIFORNIA (US) | 1990-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | MEN1 4869/4885KMT2A 1734/4885PIK3CD 3833/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | MEN1 4869/4885KMT2A 1734/4885PIK3CD 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.